Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2024 ...

Patient Capital Management highlighted stocks like Precigen, Inc. (NASDAQ:PGEN) in the fourth quarter 2024 investor letter.

$PGEN ($PGEN) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of ...

Precigen (PGEN) reported better-than-expected first-quarter earnings and is making strides toward commercializing its lead asset, PRGN-2012, for recurrent respiratory papillomatosis. The FDA has ...